Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Clinical Nutrition |
| Vol/bind | 59 |
| Udgave nummer | 7 |
| Sider (fra-til) | 843-50 |
| Antal sider | 7 |
| ISSN | 0954-3007 |
| DOI | |
| Status | Udgivet - 2005 |
Bibliografisk note
Keywords: Anticholesteremic Agents; Blood Flow Velocity; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Female; Humans; Hypercholesterolemia; Insulin; Lipids; Male; Middle Aged; Postprandial Period; Soybean Proteins; VasodilationAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: European Journal of Clinical Nutrition, Bind 59, Nr. 7, 2005, s. 843-50.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects
AU - Hermansen, K
AU - Hansen, B
AU - Jacobsen, R
AU - Clausen, P
AU - Dalgaard, M
AU - Dinesen, B
AU - Holst, J J
AU - Pedersen, E
AU - Astrup, A
N1 - Keywords: Anticholesteremic Agents; Blood Flow Velocity; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Female; Humans; Hypercholesterolemia; Insulin; Lipids; Male; Middle Aged; Postprandial Period; Soybean Proteins; Vasodilation
PY - 2005
Y1 - 2005
N2 - BACKGROUND: Studies on soy supplementation suggest a cardioprotective potential. OBJECTIVE: To examine the effects on LDL cholesterol and arterial function as a result of dietary enrichment with soy supplementation. DESIGN: A Randomized, double blind, parallel intervention trial. SETTING: Department of Endocrinology and Metabolism C, Aarhus University Hospital, and Department of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark. SUBJECTS: In all, 100 hypercholesterolaemic but otherwise healthy subjects were included in the study of which 89 completed it. INTERVENTIONS: Subjects were randomly assigned to 24 weeks of daily intake of either a soy supplement, Abalon (30 g soy protein, 9 g cotyledon fibre and 100 mg isoflavones) or placebo (30 g of casein). The soy supplement and placebo were provided in two sachets daily that were stirred in water. Fasting plasma lipids, TNF-alpha, homocysteine, insulin sensitivity, homeostasis model assessment (HOMA-IR), serum insulin, serum glucose, blood pressure as well as Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and plasma lipids to a fat-rich meal were recorded before and after the intervention. In a sub study in 32 subjects, arterial dilatory capacity, compliance, and distensibility were recorded before and after the intervention. RESULTS: In the main study, no difference in fasting plasma lipid levels or insulin sensitivity was found between soy-based supplement and placebo. A significant postprandial increase in GIP to the meal test was observed in the soy group (P < 0.05). In a substudy, no difference between the groups in changes in flow-mediated vasodilatation (P = 0.84) was detected, while the soy supplementation caused a reduction in LDL and total cholesterol. CONCLUSIONS: No significant effects on blood lipids were observed in the main study to a soy supplementation in hypercholesterolaemic subjects after 24 weeks. In the substudy, the soy supplementation, however, reduced LDL and total cholesterol but did not influence markers of arterial function.
AB - BACKGROUND: Studies on soy supplementation suggest a cardioprotective potential. OBJECTIVE: To examine the effects on LDL cholesterol and arterial function as a result of dietary enrichment with soy supplementation. DESIGN: A Randomized, double blind, parallel intervention trial. SETTING: Department of Endocrinology and Metabolism C, Aarhus University Hospital, and Department of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark. SUBJECTS: In all, 100 hypercholesterolaemic but otherwise healthy subjects were included in the study of which 89 completed it. INTERVENTIONS: Subjects were randomly assigned to 24 weeks of daily intake of either a soy supplement, Abalon (30 g soy protein, 9 g cotyledon fibre and 100 mg isoflavones) or placebo (30 g of casein). The soy supplement and placebo were provided in two sachets daily that were stirred in water. Fasting plasma lipids, TNF-alpha, homocysteine, insulin sensitivity, homeostasis model assessment (HOMA-IR), serum insulin, serum glucose, blood pressure as well as Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and plasma lipids to a fat-rich meal were recorded before and after the intervention. In a sub study in 32 subjects, arterial dilatory capacity, compliance, and distensibility were recorded before and after the intervention. RESULTS: In the main study, no difference in fasting plasma lipid levels or insulin sensitivity was found between soy-based supplement and placebo. A significant postprandial increase in GIP to the meal test was observed in the soy group (P < 0.05). In a substudy, no difference between the groups in changes in flow-mediated vasodilatation (P = 0.84) was detected, while the soy supplementation caused a reduction in LDL and total cholesterol. CONCLUSIONS: No significant effects on blood lipids were observed in the main study to a soy supplementation in hypercholesterolaemic subjects after 24 weeks. In the substudy, the soy supplementation, however, reduced LDL and total cholesterol but did not influence markers of arterial function.
U2 - 10.1038/sj.ejcn.1602151
DO - 10.1038/sj.ejcn.1602151
M3 - Journal article
C2 - 15900307
SN - 0954-3007
VL - 59
SP - 843
EP - 850
JO - European Journal of Clinical Nutrition
JF - European Journal of Clinical Nutrition
IS - 7
ER -